0
0
May 17, 2025 – A groundbreaking new study has revealed that Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), once considered a near-certain death sentence, is now highly treatable thanks to advances in targeted therapies and immunotherapy. The research, led by Dr. Robin Foa of Sapienza University in Rome and published in the New England Journal of Medicine, shows that long-term survival rates for adults with Ph+ ALL have soared to 75%-80%-without the need for traditional chemotherapy or stem cell transplantation.
Revolutionary Treatment Protocol
Since 2000, researchers have been exploring a protocol that combines tyrosine kinase inhibitors (TKIs) with glucocorticoids for induction therapy. Unlike conventional approaches, this regimen omits systemic chemotherapy. The study analyzed the effectiveness of first-, second-, and third-generation TKIs in adults aged 18 and older, with no upper age limit.
Patients received dasatinib for 84 days alongside glucocorticoids for the first 32 days. The results were striking: hematologic complete responses were achieved in 94%-100% of adults across all age groups, with minimal toxic side effects.
Impressive Survival Outcomes
-
At 20 months, overall survival was 69.2%, and disease-free survival was 51.1%.
-
Among patients over 60 who were ineligible for chemotherapy or transplantation, 94% achieved complete hematologic remission at six weeks, and two-year overall survival reached 64%.
-
The addition of the immunotherapy drug blinatumomab further boosted molecular response rates to 60% after two cycles, with continued improvement over time.
-
At a median follow-up of 18 months, overall survival climbed to 95%, and disease-free survival reached 88%.
Expert Perspective
“This progress is an illuminating example of how a better understanding of the biology of a disease, the implementation of targeted treatment directed toward the underlying genetic defect, accurate molecular monitoring, and the addition of immunotherapy has provided a cure in most affected patients,” the study authors wrote.
Cautions and Limitations
Despite the remarkable outcomes, the study reported some challenges:
-
Cardiac adverse events occurred in 29.5% of patients.
-
Vascular adverse events were seen in 27.3%.
-
High rates of dose reductions (43.2%), treatment interruptions (43.2%), and discontinuations (27.3%) suggest that starting with a lower dose may be safer for some patients.
Looking Ahead
The findings represent a major leap forward in the treatment of Ph+ ALL, offering hope to patients who previously faced grim prognoses. Ongoing research aims to further refine these protocols, reduce side effects, and expand access to these life-saving therapies.
Disclaimer:
This article is for informational purposes only and is based on research published in the New England Journal of Medicine and summarized on Medscape. It does not constitute medical advice. Patients should consult their healthcare providers for diagnosis and treatment options tailored to their individual needs.
Citations:
